Type 2 diabetes and the skeleton: new insights into sweet bones
Summary Substantial evidence shows that skeletal fragility should be considered among the complications associated with type 2 diabetes. Individuals with type 2 diabetes have increased fracture risk, despite normal bone mineral density (BMD) and high BMI–factors that are generally protective against...
Gespeichert in:
| Veröffentlicht in: | The lancet. Diabetes & endocrinology 2016-02, Vol.4 (2), p.159-173 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 173 |
|---|---|
| container_issue | 2 |
| container_start_page | 159 |
| container_title | The lancet. Diabetes & endocrinology |
| container_volume | 4 |
| creator | Shanbhogue, Vikram V, MD Mitchell, Deborah M, MD Rosen, Clifford J, Prof Bouxsein, Mary L, Dr |
| description | Summary Substantial evidence shows that skeletal fragility should be considered among the complications associated with type 2 diabetes. Individuals with type 2 diabetes have increased fracture risk, despite normal bone mineral density (BMD) and high BMI–factors that are generally protective against fractures. The mechanisms underlying skeletal fragility in diabetes are not completely understood, but are multifactorial and likely include effects of obesity, hyperglycaemia, oxidative stress, and accumulation of advanced glycation end products, leading to altered bone metabolism, structure, and strength. Clinicians should be aware that BMD measurements underestimate fracture risk in people with type 2 diabetes, and that new treatments for diabetes, with neutral or positive effects on skeletal health, might play a part in the management of diabetes in those at high risk of fracture. Data for the optimum management of osteoporosis in patients with type 2 diabetes are scarce, but in the absence of evidence to the contrary, physicians should follow guidelines established for postmenopausal osteoporosis. |
| doi_str_mv | 10.1016/S2213-8587(15)00283-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1761472290</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2213858715002831</els_id><sourcerecordid>1761472290</sourcerecordid><originalsourceid>FETCH-LOGICAL-c542t-1f666fc74aea3a24c645ce0b57829c11ad045625a5500635e4e955e1beed390b3</originalsourceid><addsrcrecordid>eNqFkE1P3DAQhq0KVBDwE1r5CIe0M3bGSXooQqgfSEgcgLPlOLPFkHW2sRe0_57sRzn0wmlGo3ee0TxCfEL4goDm661SqIua6uoU6QxA1brAD-JwN25o762vqwNxktIjACCQNjV8FAfKaEMG6FCc360WLJXsgms5c5IudjI_sExP3HMe4jcZ-UWGmMKfh5ymJg8yvTBn2Q6R07HYn7k-8cmuHon7nz_uLn8X1ze_ri4vrgtPpcoFzowxM1-Vjp12qvSmJM_QUlWrxiO6DkoyihwRgNHEJTdEjC1zpxto9ZE43XIX4_B3ySnbeUie-95FHpbJYmWwrJRqYIrSNurHIaWRZ3YxhrkbVxbBrvXZjT67dmOR7EafxWnv8-7Esp1z97b1T9YUON8GeHr0OfBokw8cPXdhZJ9tN4R3T3z_j-D7EIN3_ROvOD0OyzFOFi3apCxsIWsG0oaA-hXS2JHU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1761472290</pqid></control><display><type>article</type><title>Type 2 diabetes and the skeleton: new insights into sweet bones</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Shanbhogue, Vikram V, MD ; Mitchell, Deborah M, MD ; Rosen, Clifford J, Prof ; Bouxsein, Mary L, Dr</creator><creatorcontrib>Shanbhogue, Vikram V, MD ; Mitchell, Deborah M, MD ; Rosen, Clifford J, Prof ; Bouxsein, Mary L, Dr</creatorcontrib><description>Summary Substantial evidence shows that skeletal fragility should be considered among the complications associated with type 2 diabetes. Individuals with type 2 diabetes have increased fracture risk, despite normal bone mineral density (BMD) and high BMI–factors that are generally protective against fractures. The mechanisms underlying skeletal fragility in diabetes are not completely understood, but are multifactorial and likely include effects of obesity, hyperglycaemia, oxidative stress, and accumulation of advanced glycation end products, leading to altered bone metabolism, structure, and strength. Clinicians should be aware that BMD measurements underestimate fracture risk in people with type 2 diabetes, and that new treatments for diabetes, with neutral or positive effects on skeletal health, might play a part in the management of diabetes in those at high risk of fracture. Data for the optimum management of osteoporosis in patients with type 2 diabetes are scarce, but in the absence of evidence to the contrary, physicians should follow guidelines established for postmenopausal osteoporosis.</description><identifier>ISSN: 2213-8587</identifier><identifier>EISSN: 2213-8595</identifier><identifier>DOI: 10.1016/S2213-8587(15)00283-1</identifier><identifier>PMID: 26365605</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Bone and Bones - drug effects ; Bone and Bones - metabolism ; Bone Density ; Bone Diseases - etiology ; Bone Diseases - physiopathology ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - metabolism ; Diabetes Mellitus, Type 2 - physiopathology ; Endocrinology & Metabolism ; Female ; Fractures, Bone - epidemiology ; Fractures, Bone - etiology ; Humans ; Hypoglycemic Agents - pharmacology ; Hypoglycemic Agents - therapeutic use ; Middle Aged ; Other</subject><ispartof>The lancet. Diabetes & endocrinology, 2016-02, Vol.4 (2), p.159-173</ispartof><rights>Elsevier Ltd</rights><rights>2016 Elsevier Ltd</rights><rights>Copyright © 2016 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c542t-1f666fc74aea3a24c645ce0b57829c11ad045625a5500635e4e955e1beed390b3</citedby><cites>FETCH-LOGICAL-c542t-1f666fc74aea3a24c645ce0b57829c11ad045625a5500635e4e955e1beed390b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26365605$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shanbhogue, Vikram V, MD</creatorcontrib><creatorcontrib>Mitchell, Deborah M, MD</creatorcontrib><creatorcontrib>Rosen, Clifford J, Prof</creatorcontrib><creatorcontrib>Bouxsein, Mary L, Dr</creatorcontrib><title>Type 2 diabetes and the skeleton: new insights into sweet bones</title><title>The lancet. Diabetes & endocrinology</title><addtitle>Lancet Diabetes Endocrinol</addtitle><description>Summary Substantial evidence shows that skeletal fragility should be considered among the complications associated with type 2 diabetes. Individuals with type 2 diabetes have increased fracture risk, despite normal bone mineral density (BMD) and high BMI–factors that are generally protective against fractures. The mechanisms underlying skeletal fragility in diabetes are not completely understood, but are multifactorial and likely include effects of obesity, hyperglycaemia, oxidative stress, and accumulation of advanced glycation end products, leading to altered bone metabolism, structure, and strength. Clinicians should be aware that BMD measurements underestimate fracture risk in people with type 2 diabetes, and that new treatments for diabetes, with neutral or positive effects on skeletal health, might play a part in the management of diabetes in those at high risk of fracture. Data for the optimum management of osteoporosis in patients with type 2 diabetes are scarce, but in the absence of evidence to the contrary, physicians should follow guidelines established for postmenopausal osteoporosis.</description><subject>Bone and Bones - drug effects</subject><subject>Bone and Bones - metabolism</subject><subject>Bone Density</subject><subject>Bone Diseases - etiology</subject><subject>Bone Diseases - physiopathology</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - metabolism</subject><subject>Diabetes Mellitus, Type 2 - physiopathology</subject><subject>Endocrinology & Metabolism</subject><subject>Female</subject><subject>Fractures, Bone - epidemiology</subject><subject>Fractures, Bone - etiology</subject><subject>Humans</subject><subject>Hypoglycemic Agents - pharmacology</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Middle Aged</subject><subject>Other</subject><issn>2213-8587</issn><issn>2213-8595</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1P3DAQhq0KVBDwE1r5CIe0M3bGSXooQqgfSEgcgLPlOLPFkHW2sRe0_57sRzn0wmlGo3ee0TxCfEL4goDm661SqIua6uoU6QxA1brAD-JwN25o762vqwNxktIjACCQNjV8FAfKaEMG6FCc360WLJXsgms5c5IudjI_sExP3HMe4jcZ-UWGmMKfh5ymJg8yvTBn2Q6R07HYn7k-8cmuHon7nz_uLn8X1ze_ri4vrgtPpcoFzowxM1-Vjp12qvSmJM_QUlWrxiO6DkoyihwRgNHEJTdEjC1zpxto9ZE43XIX4_B3ySnbeUie-95FHpbJYmWwrJRqYIrSNurHIaWRZ3YxhrkbVxbBrvXZjT67dmOR7EafxWnv8-7Esp1z97b1T9YUON8GeHr0OfBokw8cPXdhZJ9tN4R3T3z_j-D7EIN3_ROvOD0OyzFOFi3apCxsIWsG0oaA-hXS2JHU</recordid><startdate>20160201</startdate><enddate>20160201</enddate><creator>Shanbhogue, Vikram V, MD</creator><creator>Mitchell, Deborah M, MD</creator><creator>Rosen, Clifford J, Prof</creator><creator>Bouxsein, Mary L, Dr</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20160201</creationdate><title>Type 2 diabetes and the skeleton: new insights into sweet bones</title><author>Shanbhogue, Vikram V, MD ; Mitchell, Deborah M, MD ; Rosen, Clifford J, Prof ; Bouxsein, Mary L, Dr</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c542t-1f666fc74aea3a24c645ce0b57829c11ad045625a5500635e4e955e1beed390b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Bone and Bones - drug effects</topic><topic>Bone and Bones - metabolism</topic><topic>Bone Density</topic><topic>Bone Diseases - etiology</topic><topic>Bone Diseases - physiopathology</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - metabolism</topic><topic>Diabetes Mellitus, Type 2 - physiopathology</topic><topic>Endocrinology & Metabolism</topic><topic>Female</topic><topic>Fractures, Bone - epidemiology</topic><topic>Fractures, Bone - etiology</topic><topic>Humans</topic><topic>Hypoglycemic Agents - pharmacology</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Middle Aged</topic><topic>Other</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shanbhogue, Vikram V, MD</creatorcontrib><creatorcontrib>Mitchell, Deborah M, MD</creatorcontrib><creatorcontrib>Rosen, Clifford J, Prof</creatorcontrib><creatorcontrib>Bouxsein, Mary L, Dr</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The lancet. Diabetes & endocrinology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shanbhogue, Vikram V, MD</au><au>Mitchell, Deborah M, MD</au><au>Rosen, Clifford J, Prof</au><au>Bouxsein, Mary L, Dr</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Type 2 diabetes and the skeleton: new insights into sweet bones</atitle><jtitle>The lancet. Diabetes & endocrinology</jtitle><addtitle>Lancet Diabetes Endocrinol</addtitle><date>2016-02-01</date><risdate>2016</risdate><volume>4</volume><issue>2</issue><spage>159</spage><epage>173</epage><pages>159-173</pages><issn>2213-8587</issn><eissn>2213-8595</eissn><abstract>Summary Substantial evidence shows that skeletal fragility should be considered among the complications associated with type 2 diabetes. Individuals with type 2 diabetes have increased fracture risk, despite normal bone mineral density (BMD) and high BMI–factors that are generally protective against fractures. The mechanisms underlying skeletal fragility in diabetes are not completely understood, but are multifactorial and likely include effects of obesity, hyperglycaemia, oxidative stress, and accumulation of advanced glycation end products, leading to altered bone metabolism, structure, and strength. Clinicians should be aware that BMD measurements underestimate fracture risk in people with type 2 diabetes, and that new treatments for diabetes, with neutral or positive effects on skeletal health, might play a part in the management of diabetes in those at high risk of fracture. Data for the optimum management of osteoporosis in patients with type 2 diabetes are scarce, but in the absence of evidence to the contrary, physicians should follow guidelines established for postmenopausal osteoporosis.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>26365605</pmid><doi>10.1016/S2213-8587(15)00283-1</doi><tpages>15</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2213-8587 |
| ispartof | The lancet. Diabetes & endocrinology, 2016-02, Vol.4 (2), p.159-173 |
| issn | 2213-8587 2213-8595 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1761472290 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Bone and Bones - drug effects Bone and Bones - metabolism Bone Density Bone Diseases - etiology Bone Diseases - physiopathology Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - metabolism Diabetes Mellitus, Type 2 - physiopathology Endocrinology & Metabolism Female Fractures, Bone - epidemiology Fractures, Bone - etiology Humans Hypoglycemic Agents - pharmacology Hypoglycemic Agents - therapeutic use Middle Aged Other |
| title | Type 2 diabetes and the skeleton: new insights into sweet bones |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T18%3A00%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Type%202%20diabetes%20and%20the%20skeleton:%20new%20insights%20into%20sweet%20bones&rft.jtitle=The%20lancet.%20Diabetes%20&%20endocrinology&rft.au=Shanbhogue,%20Vikram%20V,%20MD&rft.date=2016-02-01&rft.volume=4&rft.issue=2&rft.spage=159&rft.epage=173&rft.pages=159-173&rft.issn=2213-8587&rft.eissn=2213-8595&rft_id=info:doi/10.1016/S2213-8587(15)00283-1&rft_dat=%3Cproquest_cross%3E1761472290%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1761472290&rft_id=info:pmid/26365605&rft_els_id=S2213858715002831&rfr_iscdi=true |